Home Uncategorized Enzalutamide Continues to Provide Substantial Long-Term OS Benefit at 8 Years for... Uncategorized Enzalutamide Continues to Provide Substantial Long-Term OS Benefit at 8 Years for Patients with Metastatic Hormone-Sensitive Prostate Cancer By Ogkologos - August 25, 2026 46 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ENZAMET (ANZUP 1304) study Source RELATED ARTICLESMORE FROM AUTHOR Saving Time for Patients and Improving Well-Being Through Mindfulness and Fitness: Research from the 2023 ASCO Quality Care Symposium FDA Approves Encorafenib with Binimetinib for Metastatic Non-Small Cell Lung Cancer with a BRAF V600E Mutation Engaging People with Low-Grade Glioma in Cancer Research MOST POPULAR Adjuvant Selpercatinib Prolongs EFS Among Patients with Stage II or IIIA... June 2, 2026 Immune Checkpoint Inhibitor-Based Systemic Therapy Combinations for Patients with HCC Amenable... January 15, 2025 This 11-Year-Old Is Starting College Next Year With A Plan To... December 31, 2021 Chris Pratt Partners with GreaterGood to Support Food Banks and Feed... December 18, 2020 Load more HOT NEWS Take a Small Step Moving Beyond BMI: Low Muscle Mass May Affect Cancer Survival New Research in Treating Non-Hodgkin Lymphoma and Predicting the Risk of... Neoadjuvant Niraparib Demonstrates Promising Antitumour Activity and Safety in Patients with...
